A Part of the University of Maryland Medical Center

• General Information About Langerhans Cell Histiocytosis (LCH)
• Stages of LCH
• Recurrent LCH
• Treatment Option Overview for LCH
• Treatment Options for LCH in Children
• Treatment Options for LCH in Adults

• Hematologic Malignancies Program

• Diagnosis and Treatment...
• Physicians and Staff
• Q&A with Dr. Maria Baer
• Patient Education...
• 
    Related Resources
• Clinical Trials
• Information for Patients

Stages of LCH

There is no staging system for Langerhans cell histiocytosis (LCH).

The extent or spread of disease is usually described as stages. There is no staging system for LCH.

Treatment of LCH is based on where LCH cells are found in the body and whether one or more body systems are affected.

LCH is described as single-system disease or multisystem disease, depending on how many body systems are affected:

• Single-system LCH: LCH is found in one part of an organ or body system (unifocal) or in more than one part of that organ or body system (multifocal).
• Multisystem LCH: LCH occurs in two or more organs or body systems.

LCH may affect low-risk organs or high-risk organs, depending on where it occurs in the body:

• Low-risk organs include the skin, bone, lymph nodes, gastrointestinal tract, pituitary gland, and central nervous system (CNS).
• High-risk organs include the liver, spleen, lung, and bone marrow.